Patents Assigned to Aventis Pasteur Limited
-
Publication number: 20090155350Abstract: The present invention provides vaccines for immunizing a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The vaccine and method employ a full-length, 5?-truncated or 3?-truncated 76 kDa protein of a strain of Chlamydia pneumoniae. Modifications are possible within the scope of this invention.Type: ApplicationFiled: February 9, 2009Publication date: June 18, 2009Applicant: AVENTIS PASTEUR LIMITEDInventors: ANDREW D. MURDIN, RAYMOND P. OOMEN, JOE WANG, PAMELA DUNN
-
Patent number: 7335370Abstract: The present invention provides a method of immunizing a host against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method involves nucleic acid immunization, including DNA immunization, and employs a vector containing a nucleotide sequence which encodes an ATP/ADP translocase of a strain of Chlamydia pneumoniae. The nucleotide sequence is operably linked to a promoter to effect expression of the ATP/ADP translocase in the host. The host may be a human host. Modifications are possible within the scope of this invention.Type: GrantFiled: July 23, 2004Date of Patent: February 26, 2008Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
-
Patent number: 7241449Abstract: Purified and isolated nucleic acid molecules are provided which encode Tbp2 proteins of M. catarrhalis strains M35, 3 and LES1. The nucleic acid sequence may be used to produce recombinant Tbp2 proteins of the strain of Moraxella free of other proteins of the Moraxella strain for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecules may be used in the diagnosis of infection.Type: GrantFiled: April 12, 1999Date of Patent: July 10, 2007Assignee: Aventis Pasteur LimitedInventors: Lisa E. Myers, Anthony B. Schryvers, Robin E. Harkness, Sheena M. Loosmore, Run-Pan Du, Yan-Ping Yang, Michel H. Klein
-
Patent number: 7015033Abstract: Expression vectors are described which permit the recombinant expression of proteins which essentially contain, in addition to nucleic acid encoding the recombinant protein, nucleic acid encoding a non-proteolytic analog of Haemophilus Hin47 protein, with or without leader sequence, or nucleic acid encoding high molecular weight proteins of non-typeable Haemophilus, which are hmwB, hmwC or hmwBC.Type: GrantFiled: May 25, 2000Date of Patent: March 21, 2006Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang
-
Patent number: 7008784Abstract: The present invention is directed toward methods for the production of non-infectious, replication-deficient, immunogenic human immunodeficiency virus (HIV)-like particles. These particles are prepared from a recombinant expression vector comprising a heterologous promoter operatively connected to a DNA molecule comprising a modified HIV genome devoid of the long terminal repeat (LTR) regulatory regions but containing at least the gag and pol genes in their natural genomic arrangement. This vector is introduced into mammalian cells to produce the particles of interest. These particles should prove useful in a number of diagnostic, virologic, and immunologic applications.Type: GrantFiled: September 3, 1999Date of Patent: March 7, 2006Assignee: Aventis Pasteur LimitedInventors: Joel Haynes, Michel Henri Klein, Benjamin Rovinski, Shi Xian Cao
-
Patent number: 6974581Abstract: A multi-component immunogenic composition confers protection on an immunized host against infection caused by Haemophilus influenzae. Such composition comprises at least two different antigens of Haemophilus influenzae, one of which is an adhesin. High molecular weight (HMW) proteins of non-typeable Haemophilus influenzae enhance the immune response in a host to a non-proteolytic analog of Hin47 protein in such immunogenic compositions with one component not impairing the immunogenicity of the other. The Haemophilus vaccine may be combined with DTP component vaccines to provide a multi-valent component vaccine without impairment of the immunogenic properties of the other antigens.Type: GrantFiled: December 15, 1998Date of Patent: December 13, 2005Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Michel H. Klein
-
Patent number: 6872814Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding an 98 kDa putative outer membrane protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 98 kDa putative outer membrane protein gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: October 27, 1999Date of Patent: March 29, 2005Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Patent number: 6855537Abstract: Strains of Leishmania and other macrophage-infecting parasites are provided which express the GM-CSF gene which are useful in treating hosts infected by the parasite and in protecting hosts against disease caused by infection of hosts by parasites. The parasites are reduced in their ability to infect or survive in macrophages and hence are attenuated. At least one gene of the parasite contributing to the virulence thereto may be functionally disabled. The attenuated strains may be used for administration to a host (a) to treat a host infected by Leishmania or (b) to confer protection against disease caused by a virulent Leishmania strain, or as a diagnostic reagent.Type: GrantFiled: September 16, 1997Date of Patent: February 15, 2005Assignee: Aventis Pasteur LimitedInventors: Barbara Papadopoulu, Marc Ouellette, Martin Olivier
-
Patent number: 6849447Abstract: Protective high molecular weight (HMW) proteins are produced recombinantly by expression from E. coli by using a promoter effective in E. coli and a nucleic acid molecule which contains a modified operon of a non-typeable strain of Haemophilus. The modified operon contains the portion only of the A region which encodes the mature HMW protein and the complete B and C regions of the operon. Enhanced levels of expression of the HMW proteins can be achieved by including the E. coli cer gene, a further copy of the portion of the A region of the operon encoding the mature protein or both in the expression vector. Nucleotide and deduced amino acid sequences of the hmw1 and hmw2 genes and HMW1 and HMW2 proteins, respectively of several non-typeable Haemophilus influenzae strain have been identified.Type: GrantFiled: December 11, 2002Date of Patent: February 1, 2005Assignee: Aventis Pasteur LimitedInventors: Sheena M. Loosmore, Yan-Ping Yang, Michel H. Klein
-
Publication number: 20040241652Abstract: The invention relates to reagents and methods for enhancing an immune response using CD36 binding region/antigen hybrid polypeptides or polynucleotides encoding the hybrid polypeptides.Type: ApplicationFiled: December 12, 2002Publication date: December 2, 2004Applicant: Aventis Pasteur LimitedInventors: William I. Cox, Jeannine P. Alexander, Scott Goebel
-
Patent number: 6811783Abstract: A protective immune response against Chlamydial infection is achieved by in vivo administration of an immunogenic composition comprising two vectors and a pharmaceutically-acceptable carrier therefor. One of the vectors comprises a first nucleotide sequence encoding a major outer membrane protein (MOMP) of a strain of Chlamydia, preferably C. pneumoniae, and a promoter sequence operatively coupled to the first nucleotide sequence for expression of the MOMP in the host. The other of the vectors comprises a second nucleotide sequence encoding a 76 kDa protein of a strain of Chlamydia, preferably C. pneumoniae, and a promoter sequence operatively coupled to the second nucleotide sequence for expression of the 76 kDa protein in the host. The protection efficiency which is achieved by the immunization procedure is enhanced over that attained with the individual vectors alone.Type: GrantFiled: September 7, 1999Date of Patent: November 2, 2004Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Pamela L. Dunn
-
Patent number: 6808713Abstract: The present invention provides a method of immunizing a host against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae. The method involves nucleic acid immunization, including DNA immunization, and employs a vector containing a nucleotide sequence which encodes an ATP/ADP translocase of a strain of Chlamydia pneumoniae. The nucleotide sequence is operably linked to a promoter to effect expression of the ATP/ADP translocase in the host. The host may be a human host. Modifications are possible within the scope of this invention.Type: GrantFiled: October 16, 2001Date of Patent: October 26, 2004Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
-
Patent number: 6764682Abstract: Adjuvant compositions for modulating an immune response to an antigen administered to a host comprise a mineral salt adjuvant and at least one other adjuvant. The compositions provide an adjuvanting effect on an antigen which is greater than the adjuvanting effect attainable by one of the adjuvants alone. An antigen is covalently bonded to a glycolipid analog to provide a discrete molecule which exhibits an enhanced adjuvanting effect on the antigen which is greater than the adjuvanting effect attainable in the absence of such covalent bonding.Type: GrantFiled: June 16, 1994Date of Patent: July 20, 2004Assignee: Aventis Pasteur LimitedInventors: Ali Kandil, Olive A. James, Michel H. Klein, Pele Chong
-
Publication number: 20040086525Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding full-length, 5′-truncated or 3′-truncated 76 kDa protein of a strain of Chlamydia pneumoniae and a promoter to effect expression of the 76 kDa protein gene in the host. Modifications are possible within the scope of this invention.Type: ApplicationFiled: June 30, 2003Publication date: May 6, 2004Applicant: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn
-
Patent number: 6693087Abstract: An isolated and purified nucleic acid molecule encoding a POMP91A protein of a strain of Chlamydia, is useful for nucleic acid immunization of a host, including a human host, against disease caused by infection by a strain of Chlamydia, particularly C. pneumoniae.Type: GrantFiled: August 20, 1999Date of Patent: February 17, 2004Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Pamela L. Dunn, Raymond P. Oomen
-
Patent number: 6686339Abstract: In summary of this disclosure, the present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a inclusion membrane protein C of a strain of Chlamydia pneumoniae and a promoter to effect expression of the inclusion membrane protein C gene in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: June 15, 2001Date of Patent: February 3, 2004Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Pamela L. Dunn, Raymond P. Oomen
-
Patent number: 6677127Abstract: Vectors containing a nucleotide sequence coding for an F protein of respiratory syncytial virus (RSV) and a promoter for such sequence, preferably a cytomegalovirus promoter, are described. Such vectors also may contain a further nucleotide sequence located adjacent to the RSV F protein encoding sequence to enhance the immunoprotective ability of the RSV F protein when expressed in vivo. Such vectors may be used to immunize a host, including a human host, by administration thereto. Such vectors also may be used to produce antibodies for detection of RSV infection in a sample.Type: GrantFiled: September 13, 1999Date of Patent: January 13, 2004Assignee: Aventis Pasteur LimitedInventors: Xiaomao Li, Mary E. Ewasyshyn, Suryaprakash Sambhara, Michel H. Klein
-
Patent number: 6676949Abstract: A host is immunized against infection by a strain of Chlamydia by initial administration of an attenuated bacteria harbouring a nucleic acid encoding a Chlamydia protein followed by administration of a Chlamydia protein in ISCOMs. This procedure enables a high level of protection to be achieved.Type: GrantFiled: December 3, 1999Date of Patent: January 13, 2004Assignees: University of Manitoba, Aventis Pasteur LimitedInventors: Robert C. Brunham, Andrew D. Murdin
-
Patent number: 6660275Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector, containing a nucleotide sequence encoding a CPN100605 polypeptide of a strain of Chlamydia pneumoniae and a promoter to effect expression of the CPN100605 polypeptide in the host. Modifications are possible within the scope of this invention.Type: GrantFiled: July 26, 1999Date of Patent: December 9, 2003Assignee: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Pamela L. Dunn
-
Publication number: 20030225017Abstract: The present invention provides a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. pneumoniae, employing a vector containing a nucleotide sequence encoding a membrane ATPase of a strain of Chlamydia pneumoniae and a promoters to effect expression of the membrane ATPase in the host. Modifications are possible within the scope of this invention.Type: ApplicationFiled: December 30, 2002Publication date: December 4, 2003Applicant: Aventis Pasteur LimitedInventors: Andrew D. Murdin, Raymond P. Oomen, Joe Wang, Pamela Dunn